Cytotoxicity of the sesquiterpene lactones neoambrosin and damsin from Ambrosia maritima against multidrug-resistant cancer cells

Frontiers in Pharmacology

Volumn 6, Issue NOV, 2015, Pages

  Saeed, Mohamed ^a   Jacob, Stefan ^b   Sandjo, Louis P ^a,c   Sugimoto, Yoshikazu ^d   Khalid, Hassan E ^e   Opatz, Till ^a   Thines, Eckhard ^a,b   Efferth, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Institut für Biotechnologie und Wirkstoff Forschung   (Germany)

^c FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^d KEIO UNIVERSITY   (Japan)

^e UNIVERSITY OF KHARTOUM   (Sudan)

Author keywords

ABC transporters; Asteraceae; EGFR; P53; Src inhibition; Targeted chemotherapy

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; DAMSIN; LACTONE; MULTIDRUG RESISTANCE PROTEIN; NEOAMBROSIN; PROTEIN P53; RESAZURIN; SESQUITERPENE; SESQUITERPENE LACTONE; UNCLASSIFIED DRUG;

AMBROSIA MARITIMA; ARTICLE; CANCER CELL; CANCER PATIENT; COLUMN CHROMATOGRAPHY; CYTOTOXICITY; ENZYME ACTIVITY; HUMAN; IMMUNOBLOTTING; MASS SPECTROMETRY; MOLECULAR DOCKING; NUCLEAR MAGNETIC RESONANCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN PHOSPHORYLATION;

EID: 84949764757     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00267     Document Type: Article

References (86)

1. Agarwal, M. L., Agarwal, A., Taylor, W. R., and Stark, G. R. (1995). p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 92, 8493-8497. doi: 10.1073/pnas.92.18.8493
2. Bai, D., Ueno, L., and Vogt, P. K. (2009). Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int. J. Cancer 125, 2863-2870. doi: 10.1002/ijc.24748
3. Barancík, M., Bohácová, V., Sedlák, J., Sulová, Z., and Breier, A. (2006). LY294, 002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur. J. Pharm. Sci. 29, 426-434. doi: 10.1016/j.ejps.2006.08.006
4. Boyer, J., Mclean, E. G., Aroori, S., Wilson, P., Mcculla, A., Carey, P. D., et al. (2004). Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin. Cancer Res. 10, 2158-2167. doi: 10.1158/1078-0432.CCR-03-0362
5. Budde, R. J., Ke, S., and Levin, V. A. (1994). Activity of pp60c-src in 60 different cell lines derived from human tumors. Cancer Biochem. Biophys. 14, 171-175.
6. Buettner, R., Mesa, T., Vultur, A., Lee, F., and Jove, R. (2008). Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol. Cancer Res. 6, 1766-1774. doi: 10.1158/1541-7786.MCR-08-0169
7. Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., et al. (1998). Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497-1501. doi: 10.1126/science.282.5393.1497
8. Cartwright, C. A., Kamps, M. P., Meisler, A. I., Pipas, J. M., and Eckhart, W. (1989). pp60c-src activation in human colon carcinoma. J. Clin. Invest. 83, 2025-2033. doi: 10.1172/JCI114113
9. Ceppi, P., Papotti, M., Monica, V., Lo Iacono, M., Saviozzi, S., Pautasso, M., et al. (2009). Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin. Mol. Cancer Ther. 8, 3066-3074. doi: 10.1158/1535-7163.MCT-09-0151
10. Chan, C. M., Jing, X., Pike, L. A., Zhou, Q., Lim, D. J., Sams, S. B., et al. (2012). Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin. Cancer Res. 18, 3580-3591. doi: 10.1158/1078-0432.CCR-11-3359
11. Chiarini, F., Del Sole, M., Mongiorgi, S., Gaboardi, G. C., Cappellini, A., Mantovani, I., et al. (2008). The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 22, 1106-1116. doi: 10.1038/leu.2008.79
12. Courtneidge, S. A. (2002). Role of Src in signal transduction pathways. The Jubilee Lecture. Biochem. Soc. Trans. 30, 11-17. doi: 10.1042/bst0300011
13. Czernilofsky, A. P., Levinson, A. D., Varmus, H. E., Bishop, J. M., Tischer, E., and Goodman, H. M. (1980). Nucleotide sequence of an avian sarcoma virus oncogene (src) and proposed amino acid sequence for gene product. Nature 287, 198-203. doi: 10.1038/287198a0
14. Devita, V. T., Serpick, A. A., and Carbone, P. P. (1970). Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann. Int. Med. 73, 881-895. doi: 10.7326/0003-4819-73-6-881
15. Dirar, A. I., Mohamed, M. A., Osman, W. J. A., Abdalgadir, H., and Khalid, H. S. (2014). A Phytopharmacological review on four antitumor medicinal plants grown in sudan. Am. J. Pharm. Technol. Res. 4, 28-41.
16. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., et al. (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 95, 15665-15670. doi: 10.1073/pnas.95.26.15665
17. Efferth, T., Konkimalla, V. B., Wang, Y. F., Sauerbrey, A., Meinhardt, S., Zintl, F., et al. (2008). Prediction of broad spectrum resistance of tumors towards anticancer drugs. Clin. Cancer Res. 14, 2405-2412. doi: 10.1158/1078-0432.CCR-07-4525
18. Efferth, T., Sauerbrey, A., Olbrich, A., Gebhart, E., Rauch, P., Weber, H. O., et al. (2003). Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol. 64, 382-394. doi: 10.1124/mol.64.2.382
19. El-Sawy, M. F., Bassiouny, H. K., and El-Magdoub, A. I. (1981). Biological combat of schistosomiasis Ambrosia maritima (Damsissa) for snail control. J. Egypt Soc. Parasitol. 11, 99-117.
20. Fletcher, J. I., Haber, M., Henderson, M. J., and Norris, M. D. (2010). ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer 10, 147-156. doi: 10.1038/nrc2789
21. Fraga, B. M. (2011). Natural sesquiterpenoids. Nat. Prod. Rep. 28, 1580-1610. doi: 10.1039/c1np00046b
22. Frank, N. Y., Margaryan, A., Huang, Y., Schatton, T., Waaga-Gasser, A. M., Gasser, M., et al. (2005). ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 65, 4320-4333. doi: 10.1158/0008-5472.CAN-04-3327
23. Frank, N. Y., Pendse, S. S., Lapchak, P. H., Margaryan, A., Shlain, D., Doeing, C., et al. (2003). Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J. Biol. Chem. 278, 47156-47165. doi: 10.1074/jbc. M308700200
24. Garcia, R., Franklin, R. A., and Mccubrey, J. A. (2006). EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. Cell Cycle 5, 2820-2826. doi: 10.4161/cc.5.23.3535
25. Gerber, D. E. (2008). Targeted therapies: a new generation of cancer treatments. Am. Fam. Physician 77, 311-319.
26. Gopal, Y. N., Chanchorn, E., and Van Dyke, M. W. (2009). Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Mol. Cancer Ther. 8, 552-562. doi: 10.1158/1535-7163.MCT-08-0661
27. Gottesman, M. M. (2002). Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627. doi: 10.1146/annurev.med.53.082901.103929
28. Gros, P., Ben-Neriah, Y., Croop, J. M., and Housman, D. E. (1986). Isolation and expression of a complementary-DNA that confers multidrug resistance. Nature 323, 728-731. doi: 10.1038/323728a0
29. Hall, M. D., Handley, M. D., and Gottesman, M. M. (2009). Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol. Sci. 30, 546-556. doi: 10.1016/j.tips.2009.07.003
30. Hanks, S. K., Quinn, A. M., and Hunter, T. (1988). The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241, 42-52. doi: 10.1126/science.3291115
31. Haynes, M. P., Li, L., Sinha, D., Russell, K. S., Hisamoto, K., Baron, R., et al. (2003). Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J. Biol. Chem. 278, 2118-2123. doi: 10.1074/jbc. M210828200
32. Herz, W., Gage, D., and Kumar, N. (1981). Damsinic acid and ambrosanolides from vegetative Ambrosia hispida. Phytochemistry 20, 1601-1604. doi: 10.1016/S0031-9422(00)98540-6
33. Hirsch-Ernst, K. I., Ziemann, C., Schmitz-Salue, C., Foth, H., and Kahl, G. F. (1995). Modulation of P-glycoprotein and mdr1b mRNA expression by growth factors in primary rat hepatocyte culture. Biochem. Biophys. Res. Commun. 215, 179-185. doi: 10.1006/bbrc.1995.2450
34. Hoffmann, K., Xiao, Z., Franz, C., Mohr, E., Serba, S., Buchler, M. W., et al. (2011). Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro. Cancer Cell Int. 11, 40. doi: 10.1186/1475-2867-11-40
35. Holohan, C., Van Schaeybroeck, S., Longley, D. B., and Johnston, P. G. (2013). Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714-726. doi: 10.1038/nrc3599
36. Huang, H. S., Nagane, M., Klingbeil, C. K., Lin, H., Nishikawa, R., Ji, X. D., et al. (1997). The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Biol. Chem. 272, 2927-2935. doi: 10.1074/jbc.272.5.2927
37. Irby, R. B., and Yeatman, T. J. (2000). Role of Src expression and activation in human cancer. Oncogene 19, 5636-5642. doi: 10.1038/sj.onc.1203912
38. Jones, G., Machado, J., and Merlo, A. (2001). Loss of focal adhesion kinase (FAK) inhibits epidermal growth factor receptor-dependent migration and induces aggregation of nh(2)-terminal FAK in the nuclei of apoptotic glioblastoma cells. Cancer Res. 61, 4978-4981.
39. Katayama, K., Yoshioka, S., Tsukahara, S., Mitsuhashi, J., and Sugimoto, Y. (2007). Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol. Cancer Ther. 6, 2092-2102. doi: 10.1158/1535-7163.MCT-07-0148
40. Kawanobe, T., Kogure, S., Nakamura, S., Sato, M., Katayama, K., Mitsuhashi, J., et al. (2012). Expression of human ABCB5 confers resistance to taxanes and anthracyclines. Biochem. Biophys. Res. Commun. 418, 736-741. doi: 10.1016/j.bbrc.2012.01.090
41. Khalid, H., Abdalla, W. E., Abdelgadir, H., Opatz, T., and Efferth, T. (2012). Gems from traditional north-African medicine: medicinal and aromatic plants from Sudan. Nat. Prod. Bioprospect. 2, 92-103. doi: 10.1007/s13659-012-0015-2
42. Kimmig, A., Gekeler, V., Neumann, M., Frese, G., Handgretinger, R., Kardos, G., et al. (1990). Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res. 50, 6793-6799.
43. Kuete, V., and Efferth, T. (2013). Molecular determinants of cancer cell sensitivity and resistance towards the sesquiterpene farnesol. Pharmazie 68, 608-615.
44. Li, F., Zhao, C., and Wang, L. (2014). Molecular-targeted agents combination therapy for cancer: developments and potentials. Int. J. Cancer 134, 1257-1269. doi: 10.1002/ijc.28261
45. Lopez-Anton, N., Hermann, C., Murillo, R., Merfort, I., Wanner, G., Vollmar, A. M., et al. (2007). Sesquiterpene lactones induce distinct forms of cell death that modulate human monocyte-derived macrophage responses. Apoptosis 12, 141-153. doi: 10.1007/s10495-006-0331-2
46. Lutz, M. P., Esser, I. B., Flossmann-Kast, B. B., Vogelmann, R., Lührs, H., Friess, H., et al. (1998). Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem. Biophys. Res. Commun. 243, 503-508. doi: 10.1006/bbrc.1997.8043
47. Maa, M. C., Leu, T. H., Mccarley, D. J., Schatzman, R. C., and Parsons, S. J. (1995). Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc. Natl. Acad. Sci. U.S.A. 92, 6981-6985. doi: 10.1073/pnas.92.15.6981
48. Mao, W., Irby, R., Coppola, D., Fu, L., Wloch, M., Turner, J., et al. (1997). Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 15, 3083-3090. doi: 10.1038/sj.onc.1201496
49. Martin, G. S. (1970). Rous sarcoma virus: a function required for the maintenance of the transformed state. Nature 227, 1021-1023. doi: 10.1038/2271021a0
50. Merfort, I. (2011). Perspectives on sesquiterpene lactones in inflammation and cancer. Curr. Drug Targets 12, 1560-1573. doi: 10.2174/138945011798109437
51. Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., et al. (2009). AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785-2791. doi: 10.1002/jcc.21256
52. Muthuswamy, S. K., Siegel, P. M., Dankort, D. L., Webster, M. A., and Muller, W. J. (1994). Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol. Cell Biol. 14, 735-743. doi: 10.1128/MCB.14.1.735
53. Nagane, M., Levitzki, A., Gazit, A., Cavenee, W. K., and Huang, H. J. (1998). Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc. Natl. Acad. Sci. U.S.A. 95, 5724-5729. doi: 10.1073/pnas.95.10.5724
54. Nautiyal, J., Majumder, P., Patel, B. B., Lee, F. Y., and Majumdar, A. P. (2009). Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett. 283, 143-151. doi: 10.1016/j.canlet.2009.03.035
55. Newman, D. J., and Cragg, G. M. (2012). Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 75, 311-335. doi: 10.1021/np200906s
56. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., et al. (1989). Mutations in the p53 gene occur in diverse human tumour types. Nature 342, 705-708. doi: 10.1038/342705a0
57. Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., et al. (1994). A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. U.S.A. 91, 7727-7731. doi: 10.1073/pnas.91.16.7727
58. Okutani, Y., Kitanaka, A., Tanaka, T., Kamano, H., Ohnishi, H., Kubota, Y., et al. (2001). Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway. Oncogene 20, 6643-6650. doi: 10.1038/sj.onc.1204807
59. Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., and Hainaut, P. (2002). The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19, 607-614. doi: 10.1002/humu.10081
60. Pick, A., and Wiese, M. (2012). Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway. ChemMedChem 7, 650-662. doi: 10.1002/cmdc.201100543
61. Piovesan, B., Pennell, N., and Berinstein, N. L. (1998). Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity. Oncogene 17, 2339-2350. doi: 10.1038/sj.onc.1202147
62. Pluchino, K. M., Hall, M. D., Goldsborough, A. S., Callaghan, R., and Gottesman, M. M. (2012). Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist. Updat. 15, 98-105. doi: 10.1016/j.drup.2012.03.002
63. Polonio-Vallon, T., Kirkpatrick, J., Krijgsveld, J., and Hofmann, T. G. (2014). Src kinase modulates the apoptotic p53 pathway by altering HIPK2 localization. Cell Cycle 13, 115-125. doi: 10.4161/cc.26857
64. Raaijmakers, M. H., De Grouw, E. P., Van Der Reijden, B. A., De Witte, T. J., Jansen, J. H., and Raymakers, R. A. (2006). ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia. Clin. Cancer Res. 12, 3452-3458. doi: 10.1158/1078-0432.CCR-05-1945
65. Roginskaya, V., Zuo, S., Caudell, E., Nambudiri, G., Kraker, A. J., and Corey, S. J. (1999). Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia 13, 855-861. doi: 10.1038/sj.leu.2401429
66. Roskoski, R. (2004). Src protein-tyrosine kinase structure and regulation. Biochem. Biophys. Res. Commun. 324, 1155-1164. doi: 10.1016/j.bbrc.2004.09.171
67. Rougier, P., and Lepère, C. (2005). Metastatic colorectal cancer: first-and second-line treatment in 2005. Semin. Oncol. 32, 15-20. doi: 10.1053/j.seminoncol.2005.07.020
68. Rous, P. (1911). A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp. Med. 13, 397-411. doi: 10.1084/jem.13.4.397
69. Saeed, M., Kuete, V., Kadioglu, O., Börtzler, J., Khalid, H., Greten, H. J., et al. (2014). Cytotoxicity of the bisphenolic honokiol from Magnolia officinalis against multiple drug-resistant tumor cells as determined by pharmacogenomics and molecular docking. Phytomedicine 21, 1525-1533. doi: 10.1016/j.phymed.2014.07.011
70. Saeed, M. E., Abdelgadir, H., Sugimoto, Y., Khalid, H. E., and Efferth, T. (2015). Cytotoxicity of 35 medicinal plants from Sudan towards sensitive and multidrug-resistant cancer cells. J. Ethnopharmacol. doi: 10.1016/j.jep.2015.07.005 [Epub ahead of print].
71. Salam, N. A. A., Mahmoud, Z. F., Ziesche, J., and Jakupovic, J. (1984). Sesquiterpene lactones from Ambrosia maritima (Damssissa). Phytochemistry 23, 2851-2853. doi: 10.1016/0031-9422(84)83028-9
72. Shapiro, D. M. (1955). Combination chemotherapy of cancer based upon quantitative biochemical differences. Surg. Forum. 5, 646-650.
73. Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., et al. (2003). Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 63, 6962-6970.
74. Silva, C. M. (2004). Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 23, 8017-8023. doi: 10.1038/sj.onc.1208159
75. Staley, C. A., Parikh, N. U., and Gallick, G. E. (1997). Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-Src. Cell Growth Differ. 8, 269-274.
76. Staudt, L. M. (2010). Oncogenic activation of NF-kappaB. Cold Spring Harb. Perspect. Biol. 2:a000109. doi: 10.1101/cshperspect.a000109
77. Summy, J. M., and Gallick, G. E. (2006). Treatment for advanced tumors: SRC reclaims center stage. Clin. Cancer Res. 12, 1398-1401. doi: 10.1158/1078-0432.CCR-05-2692
78. Sun, Y., St Clair, D. K., Xu, Y., Crooks, P. A., and St Clair, W. H. (2010). A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. Cancer Res. 70, 2880-2890. doi: 10.1158/0008-5472.CAN-09-4572
79. Tice, D. A., Biscardi, J. S., Nickles, A. L., and Parsons, S. J. (1999). Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc. Natl. Acad. Sci. U.S.A. 96, 1415-1420. doi: 10.1073/pnas.96.4.1415
80. Ueda, K., Cornwell, M. M., Gottesman, M. M., Pastan, I., Roninson, I. B., Ling, V., et al. (1986). The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem. Biophys. Res. Commun. 141, 956-962. doi: 10.1016/S0006-291X(86)80136-X
81. Villagomez, R., Rodrigo, G. C., Collado, I. G., Calzado, M. A., Munoz, E., Akesson, B., et al. (2013). Multiple anticancer effects of damsin and coronopilin isolated from Ambrosia arborescens on cell cultures. Anticancer. Res. 33, 3799-3805.
82. Vogelstein, B., Lane, D., and Levine, A. J. (2000). Surfing the p53 network. Nature 408, 307-310. doi: 10.1038/35042675
83. Waldman, T., Kinzler, K. W., and Vogelstein, B. (1995). p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55, 5187-5190.
84. Yeatman, T. J. (2004). A renaissance for SRC. Nat. Rev. Cancer 4, 470-480. doi: 10.1038/nrc1366
85. Zhang, S., Won, Y. K., Ong, C. N., and Shen, H. M. (2005). Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr. Med. Chem. Anticancer Agents 5, 239-249. doi: 10.2174/1568011053765976
86. Zhao, Q., Kretschmer, N., Bauer, R., and Efferth, T. (2015). Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib. Int. J. Cancer 137, 1446-1456. doi: 10.1002/ijc.29483